More about Dr. Lal PathLabs Limited
Fundamentals for Dr. Lal PathLabs Limited
Regulatory Filings for Dr. Lal PathLabs Limited
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
Fundamentals for Dr. Lal PathLabs Limited
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.
Revenue projections:
Dr. Lal PathLabs Limited is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.
Financial Ratios:
| currentRatio | 3.47600 |
|---|---|
| forwardPE | 38.93565 |
| debtToEquity | 7.83100 |
| earningsGrowth | -0.15400 |
| revenueGrowth | 0.16600 |
| grossMargins | 0.62434 |
| operatingMargins | 0.20236 |
| trailingEps | 31.65000 |
| forwardEps | 41.19618 |
LALPATHLAB's current ratio is 3.476, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting LALPATHLAB has no trouble covering its short-term financial obligations.
LALPATHLAB's low earnings and revenue growth suggest that the company may see declining profits. This indicates potential financial challenges ahead, and could lead to a more cautious outlook from investors.
With positive gross and operating margins, Dr. Lal PathLabs Limited demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
LALPATHLAB's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that LALPATHLAB is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.
Price projections:
The price of LALPATHLAB has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.
Insider Transactions:
42 sales transactions of LALPATHLAB were conducted, with market price at 2768.952378045945.There were 1 buy transactions of LALPATHLAB, with market price at 3308.5.Insider transactions show no notable pattern, making it difficult to discern whether these actions signal positive or negative developments within the company.
Recommendation changes over time:
Analysts have shown a buy bias for Dr. Lal PathLabs Limited, marking it as a favorable investment option. This could inspire investors to see Dr. Lal PathLabs Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
How Independent Directors Failed Rs 2,500 Crore in Value
India’s Stock Market May Be Sitting on a Trap